Shots:
Minaris is advancing its dual-business strategy through specialized Advanced Therapies and Advanced Testing units, enabling sponsors to streamline development, manufacturing, biosafety testing, and commercialization within one integrated global organization.
Minaris is focused on solving key cell & gene therapy manufacturing challenges by reducing variability, accelerating tech transfer, improving “first time right” execution, and lowering…
Shots:
The company has filed a P-I/II IND with the FDA to begin clinical trials of CYPS317 for mod. to sev. Psoriasis
In animal studies, a single dose of CYPS317 matched or exceeded multiple anti-IL-23 mAb doses, showing durable effects and reduced disease recurrence
CYPS317 is an investigational allogeneic fibroblast spheroid therapy for mod. to…

